Market Cap : 1 B | Enterprise Value : 894.65 M | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Myovant Sciences's annualized positive value of Interest Expense for the quarter that ended in Mar. 2022 was $14.0 Mil. Myovant Sciences's average total debt for the quarter that ended in Mar. 2022 was $368.1 Mil. Therefore, Myovant Sciences's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2022 was 3.80%.
The historical data trend for Myovant Sciences's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Myovant Sciences's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Effective Interest Rate on Debt % falls into.
Myovant Sciences's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Mar. 2022 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (A: Mar. 2021 ) | + | Total Debt (A: Mar. 2022 )) | / count ) |
= | -1 * -13.971 | / | ( (369.696 | + | 367.889) | / 2 ) |
= | -1 * -13.971 | / | 368.7925 | |||
= | 3.79 % |
where
Total Debt (A: Mar. 2021 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 367.889 | + | 1.807 |
= | 369.696 |
Total Debt (A: Mar. 2022 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 365.741 | + | 2.148 |
= | 367.889 |
Myovant Sciences's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2022 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (Q: Dec. 2021 ) | + | Total Debt (Q: Mar. 2022 )) | / count ) |
= | -1 * -13.972 | / | ( (368.37 | + | 367.889) | / 2 ) |
= | -1 * -13.972 | / | 368.1295 | |||
= | 3.80 % |
where
Total Debt (Q: Dec. 2021 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 366.318 | + | 2.052 |
= | 368.37 |
Total Debt (Q: Mar. 2022 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 365.741 | + | 2.148 |
= | 367.889 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2022) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Thank you for viewing the detailed overview of Myovant Sciences's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.
Potter Myrtle S | director | 10 FINDERNE AVE BRIDGEWATER NJ 08807 |
Guinan Mark | director | C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094 |
Arjona Ferreira Juan Camilo | officer: Chief Medical Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Curran Terrie | director | C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Gulfo Adele M. | director | ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957 |
Sebelius Kathleen | director | C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025 |
Lang Matthew | officer: General Counsel & Corp. Secy. | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 60 WALL STREET NEW YORK NY 10005 |
Seely Lynn | director, officer: Principal Executive Officer | 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107 |
Sablich Kim | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Nomura Hiroshi | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 |
Torti Frank | director | 2855 SAND HILL ROAD MENLO PARK CA 94025 |
From GuruFocus
Other Sources
By Zacks 2021-09-10
By tipranks.com 2022-02-16
By Fool 2020-12-28
By Zacks 2021-02-11
By Seekingalpha 2021-02-11
By Zacks 2021-10-26
By Seekingalpha 2021-07-28
By Seekingalpha 2020-12-22
By Zacks 2021-05-11
By Zacks 2020-12-29
By Seekingalpha 2022-01-02
By Zacks 2020-12-29